Ninoxan (Nitrous Oxide, Oxygen)

Nitrous oxide, the active ingredient in Ninoxan, is an analgesic and anesthetic gas presented as a medical gas for inhalation use. It provides analgesia and sedation for minor procedures and supplies supplemental oxygen to support respiration during diagnostic or therapeutic interventions.

GNH USA supplies Ninoxan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory‑compliant documentation for import and distribution, ensuring reliable supply chains across multiple continents.

Ninoxan is used in clinical settings where analgesia or sedation is required for minor procedures and where supplemental oxygen support is beneficial.

- Minor surgical or dental procedures: provides rapid analgesia and mild sedation to improve patient comfort. - Diagnostic imaging or endoscopic examinations: offers conscious sedation while maintaining spontaneous breathing. - Supplemental oxygen therapy: delivers additional oxygen to patients with transient hypoxia during procedures.

Ninoxan may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea - Dizziness - Headache - Mild euphoria - Increased salivation - Vomiting

Serious or Rare Side Effects: - Hypoxia - Respiratory depression - Severe hypotension - Loss of consciousness - Allergic reactions such as rash or bronchospasm - Rare cases of malignant hyperthermia

Ninoxan requires specific safety measures to minimise risk and ensure optimal patient outcomes.

- Assess patient history: screen for contraindications such as severe COPD, pneumothorax, or recent middle‑ear surgery. - Monitor ventilation: continuously observe respiratory rate, oxygen saturation, and end‑tidal CO₂ during administration. - Use titrated flow: adjust nitrous oxide concentration to the lowest effective level to achieve desired effect. - Avoid prolonged exposure: limit total inhalation time to reduce risk of vitamin B12 depletion and neurotoxicity. - Provide emergency equipment: have a scavenging system and resuscitation tools readily available. - Store at ambient temperature: keep cylinders in a well‑ventilated, dry area below 25 °C, protected from direct sunlight and heat sources.

Ninoxan can interact with other agents that affect the central nervous system or respiratory function, requiring careful management.

Major Interactions (Avoid): - Volatile anesthetics: additive CNS depression may occur. - Sedative‑hypnotics (e.g., benzodiazepines, barbiturates): enhanced sedation and respiratory depression. - High‑concentration oxygen therapy: may reduce nitrous oxide efficacy.

Moderate Interactions (Monitor Closely): - Certain antidepressants (e.g., SSRIs): potential increase in serotonin syndrome risk. - Nitrous oxide‑sensitive conditions (e.g., methionine synthase deficiency): may exacerbate metabolic effects. - Inhaled bronchodilators: may alter respiratory response during gas administration.